Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies: 5-year follow-up of a pivotal Phase II study
  • Budde, Elizabeth
  • Sehn, Laurie
  • Matasar, Matthew
  • Schuster, Stephen
  • Assouline, Sarit
  • ... Kim, Won-Seog
  • 외 14명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies: 5-year follow-up of a pivotal Phase II study
저자
Budde, ElizabethSehn, LaurieMatasar, MatthewSchuster, StephenAssouline, SaritKuruvilla, JohnKim, Won-SeogCheah, ChanShadman, MazyarDietrich, SaschaKu, MatthewEl-Sharkawi, DimaGutierrez, NormaWei, Michael C.Yin, ShenSit, JasonTracy, SamuelSabalvaro, FidelisPeneul, EliciaBartlett, Nancy
DOI
10.1182/blood-2025-5352
발행일
2025-11-03
유형
Meeting Abstract
저널명
Blood
146
페이지
5352 ~ 5353